Congenital adrenal hyperplasia

Congenital adrenal hyperplasia (CAH) is a group of inherited genetic disorders affecting the adrenal glands, which are located atop the kidneys. These glands produce essential hormones, including cortisol and aldosterone, as well as androgens like testosterone. In CAH, a deficiency in specific enzymes disrupts hormone production, leading to a range of physical, metabolic, and developmental consequences. The most common form, accounting for about 95% of cases, is 21-hydroxylase deficiency. This condition is typically diagnosed in infancy or early childhood but can also manifest later in life, depending on the severity of the enzyme deficiency.

Etiology and Genetic Basis

CAH is primarily caused by mutations in genes responsible for steroidogenesis, the process by which the adrenal glands synthesize hormones. The most prevalent mutation affects the CYP21A2 gene, which encodes the 21-hydroxylase enzyme. This enzyme is critical for converting precursor molecules into cortisol and aldosterone. When the enzyme is deficient, the adrenal glands produce excess androgens while failing to synthesize sufficient cortisol and aldosterone. Other, rarer forms of CAH involve mutations in genes such as CYP11B1 (11β-hydroxylase deficiency) or CYP17A1 (17α-hydroxylase deficiency), each causing distinct hormonal imbalances.

Clinical Manifestations

Symptoms of CAH vary widely depending on the enzyme deficiency and the age of onset. In severe cases, such as classic 21-hydroxylase deficiency, affected individuals may exhibit salt-wasting crises in infancy, characterized by dehydration, low blood pressure, and electrolyte imbalances. These crises can be life-threatening if untreated. In females, excess androgen production can lead to ambiguous genitalia at birth or early puberty, while males may experience accelerated growth and early puberty. Non-classic forms of CAH, which are milder, may present with symptoms such as acne, hirsutism (excessive hair growth), or irregular menstrual cycles in females.

Diagnosis and Screening

Diagnosis often begins with newborn screening programs that measure 17-hydroxyprogesterone levels, a precursor to cortisol that accumulates in CAH. Elevated levels may prompt further testing, including blood hormone assays and genetic analysis. In older individuals, symptoms such as virilization or metabolic issues may lead to diagnostic evaluation. Imaging studies like abdominal ultrasound may be used to assess adrenal gland size or structure, though they are not routinely required.

Management and Treatment

Treatment for CAH focuses on hormone replacement to normalize cortisol and aldosterone levels while suppressing excessive androgen production. Glucocorticoids (e.g., hydrocortisone) are the mainstay of therapy, with mineralocorticoids (e.g., fludrocortisone) added in cases of aldosterone deficiency. In severe salt-wasting crises, emergency intravenous corticosteroids and saline infusions are required. Regular monitoring of hormone levels, growth, and bone health is essential. In some cases, surgical intervention may be necessary to address genital abnormalities or complications.

Prognosis and Long-Term Considerations

With appropriate treatment, individuals with CAH can lead healthy lives. However, lifelong hormone replacement and regular medical follow-up are necessary. Untreated or poorly managed cases can lead to complications such as infertility, osteoporosis, or cardiovascular disease. Psychological support is also important, particularly for individuals with visible genital differences or those experiencing gender identity concerns.

Research and External Resources

For further reading on the scientific basis of sex differences related to Congenital adrenal hyperplasia, see [1]. This resource explores how hormonal imbalances, including those seen in CAH, influence biological sex differences.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3182719/

This page contains information generated by Ollama. The information was reviewed, and may have been altered, by a human editor before being added to the Featured category. As of July 2026 information generated by AI is not subject to copyright and is thus in the public domain. This page is pending human review.